Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

594

10.17650/1994-4098-2018-14-2-54-60

MAMMOLOGY. REVIEWS

МАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИ

THE ROLE OF OVARIAN SUPPRESSION IN THE TREATMENT OF EARLY-STAGE HORMONE-SENSITIVE BREAST CANCER

РОЛЬ ОВАРИАЛЬНОЙ СУПРЕССИИ В ТЕРАПИИ РАННЕГО ГОРМОНОЧУВСТВИТЕЛЬНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Koroleva

I. A.

Королева

И. А.

Russian Federation

Department of Clinical Medicine in Postgraduate Education

227 Chapaevskaya St., Samara 443001

Кафедра клинической медицины последипломного образования

443001 Самара, ул. Чапаевская, 227

Ирина Альбертовна Королева

korolevaia_samara@mail.ru

Kopp

M. V.

Копп

М. В.

Russian Federation

Department of Clinical Medicine in Postgraduate Education

227 Chapaevskaya St., Samara 443001

Кафедра клинической медицины последипломного образования

443001 Самара, ул. Чапаевская, 227

Medical University «Reaviz»Медицинский университет «Реавиз»

15082018

142

54601508201815082018

https://ojrs.abvpress.ru/ojrs/article/view/594

Ovarian suppression (OS) is an effective method of treating hormone sensitive breast cancer. The combination of OS and tamoxifen in breast cancer is more effective than any of these methods used as monotherapy. A number of clinical trials confirmed the need for OS chemotherapy in patients with hormone-positive operable breast cancer, because women retained their menstrual function for 5 years. OS chemotherapy during adjuvant chemotherapy allows preserving fertility in patients with breast cancer.

Овариальная супрессия (ОС) является эффективным методом терапии гормоночувствительного рака молочной железы. Комбинация ОС и тамоксифена при раке молочной железы эффективнее, чем каждый из этих методов, применяемый в виде монотерапии. В ряде клинических исследований была подтверждена необходимость медикаментозной ОС больным гормоноположительным операбельным раком молочной железы, которые сохранили менструальную функцию, в составе адъювантной гормонотерапии в течение 5 лет. Назначение лекарственной ОС на период адъювантной химиотерапии позволяет сохранить фертильность пациенток.

breast cancerhormone therapyovarian suppressiongonadotropin-releasing hormone analoguestamoxifenexemestane

рак молочной железыгормональная терапияовариальная супрессияаналоги гонадотропин-рилизинг-гормонатамоксифенэксеместан

1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64(1):52–62. PMID: 24114568. DOI: 10.3322/caac.21203.

DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64(1):52–62. PMID: 24114568. DOI: 10.3322/caac.21203.

2. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2009. C. 38– 43. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2009. Pp. 38–43. (In Russ.)].

Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2009. C. 38– 43. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2009. Pp. 38–43. (In Russ.)].

3. Beatson G. On the treatment of inoperable 10 cases of carcinoma of the mamma: suggestions for a new method of treatment of illustrative cases. Trans Med Chir Soc Edinb 1896;15:153–79. PMID: 29584099.

Beatson G. On the treatment of inoperable 10 cases of carcinoma of the mamma: suggestions for a new method of treatment of illustrative cases. Trans Med Chir Soc Edinb 1896;15:153–79. PMID: 29584099.

4. KNCCN Clinical Practice Guidelines: breast cancer. Version 2.2016. Available at: https://www.nccn.org.

KNCCN Clinical Practice Guidelines: breast cancer. Version 2.2016. Available at: https://www.nccn.org.

5. Cardoso F., Costa A., Norton L. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2). Breast 2014;23(5): 489–502. PMID: 25244983. DOI: 10.1016/j.breast.2014.08.009.

Cardoso F., Costa A., Norton L. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2). Breast 2014;23(5): 489–502. PMID: 25244983. DOI: 10.1016/j.breast.2014.08.009.

6. Conte C.C., Nemoto T., Rosner D. Dao T.L. Therapeutic oophorectomy in metastatic breast cancer. Cancer 1989;64(1):150–3. PMID: 2731111.

Conte C.C., Nemoto T., Rosner D. Dao T.L. Therapeutic oophorectomy in metastatic breast cancer. Cancer 1989;64(1):150–3. PMID: 2731111.

7. Oriana S., Bohm S., Baeli A. et al. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer. Eur J Surg Oncol 1989;15(1):39–42. PMID: 2917664.

Oriana S., Bohm S., Baeli A. et al. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer. Eur J Surg Oncol 1989;15(1):39–42. PMID: 2917664.

8. Petru E., Pickel H., Heydarfadai M. et al. Non-genital cancers metastatic to ovary. Gynecol Oncol 1992;44(1):83–6. PMID: 1730431.

Petru E., Pickel H., Heydarfadai M. et al. Non-genital cancers metastatic to ovary. Gynecol Oncol 1992;44(1):83–6. PMID: 1730431.

9. Mazur M.T., Hsueh S., Gersell D.J. Metastases to the female genital tract. Analysis of 325 cases. Cancer 1984;53(9):1978–84. PMID: 6322966.

Mazur M.T., Hsueh S., Gersell D.J. Metastases to the female genital tract. Analysis of 325 cases. Cancer 1984;53(9):1978–84. PMID: 6322966.

10.

10. Le Bouedec G., de Latour M., Levrel O., Dauplat J. Tumeurs de Krukenberg d’origine mammaire. Press Med 1997;26:454–8.

Le Bouedec G., de Latour M., Levrel O., Dauplat J. Tumeurs de Krukenberg d’origine mammaire. Press Med 1997;26:454–8.

11.

11. Аrora R.S., Patel S.M., Sinha V. Nongenital cancers metastatic to the ovary: our experience. GCSMC J Med Sci 2015;4(2):102–7.

Аrora R.S., Patel S.M., Sinha V. Nongenital cancers metastatic to the ovary: our experience. GCSMC J Med Sci 2015;4(2):102–7.

12.

12. Clarke M.J. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ 1998; 317(7167):1246–8. PMID: 9794874.

Clarke M.J. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ 1998; 317(7167):1246–8. PMID: 9794874.

13.

13. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348(9036):1189–96. PMID: 8898035.

Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348(9036):1189–96. PMID: 8898035.

14.

14. Lees A.W., Giuffre C., Burns P.E. et al. Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet 1980;151(6):721–4. PMID: 7444722.

Lees A.W., Giuffre C., Burns P.E. et al. Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet 1980;151(6):721–4. PMID: 7444722.

15.

15. Limonta P., Montagnani M.M., Moretti R.M. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10(4):709–20. PMID: 11281820. DOI: 10.1517/13543784.10.4.709.

Limonta P., Montagnani M.M., Moretti R.M. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10(4):709–20. PMID: 11281820. DOI: 10.1517/13543784.10.4.709.

16.

16. Harvey H.A., Lipton A., Max D.T. et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol 1985;3(8):1068–72. PMID: 3926958. DOI: 10.1200/JCO. 1985.3.8.1068.

Harvey H.A., Lipton A., Max D.T. et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol 1985;3(8):1068–72. PMID: 3926958. DOI: 10.1200/JCO. 1985.3.8.1068.

17.

17. Papakonstantinou A., Foukakis T., Rodriguez-Wallberg K.A., Bergh J. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol 2016;34(14):1573–9. PMID: 26951320. DOI: 10.1200/JCO. 2015.65.3493.

Papakonstantinou A., Foukakis T., Rodriguez-Wallberg K.A., Bergh J. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol 2016;34(14):1573–9. PMID: 26951320. DOI: 10.1200/JCO. 2015.65.3493.

18.

18. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14(5):1718–29. PMID: 8622093. DOI: 10.1200/JCO.1996.14.5.1718.

Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14(5):1718–29. PMID: 8622093. DOI: 10.1200/JCO.1996.14.5.1718.

19.

19. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2016;4(спецвыпуск 2):97–122. [SteninaM.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for invasive breast cancer chemotherapy. Malignant tumors 2016;4 (special issue 2):97–122. (In Russ.)].

Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2016;4(спецвыпуск 2):97–122. [SteninaM.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for invasive breast cancer chemotherapy. Malignant tumors 2016;4 (special issue 2):97–122. (In Russ.)].

20.

20. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451–67. PMID: 9605801.

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451–67. PMID: 9605801.

21.

21. International Breast Cancer Study Group, Colleoni M., Gelbert S. et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 2006;24(9):1332–41. PMID: 16505417. DOI: 10.1200/JCO.2005.03.0783.

International Breast Cancer Study Group, Colleoni M., Gelbert S. et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 2006;24(9):1332–41. PMID: 16505417. DOI: 10.1200/JCO.2005.03.0783.

22.

22. LHRH-agonists in Early Breast Cancer Overview Group, Cuzick J., Ambroisine L. et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet 2007;369(9574):1711–23. PMID: 17512856. DOI: 10.1016/S0140- 6736(07)660778–8.

LHRH-agonists in Early Breast Cancer Overview Group, Cuzick J., Ambroisine L. et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet 2007;369(9574):1711–23. PMID: 17512856. DOI: 10.1016/S0140- 6736(07)660778–8.

23.

23. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal woman with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359(9324):2131–9. PMID: 12090977.

The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal woman with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359(9324):2131–9. PMID: 12090977.

24.

24. СG ESMO 2015, CG ASCO 2016, CG NCCN 2014.

СG ESMO 2015, CG ASCO 2016, CG NCCN 2014.

25.

25. Francis P.A., Regan M.M., Fleming G.F. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372(5):436–46. PMID: 25495490. DOI: 10.1056/NNEJMo1412379.

Francis P.A., Regan M.M., Fleming G.F. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372(5):436–46. PMID: 25495490. DOI: 10.1056/NNEJMo1412379.

26.

26. Pagani O., Regan M.M., Walley B.A. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;37192:107–18. PMID: 24881463. DOI: 10.1056/NNEJMo1404037.

Pagani O., Regan M.M., Walley B.A. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;37192:107–18. PMID: 24881463. DOI: 10.1056/NNEJMo1404037.

27.

27. Fleming G., Francis P.A., Lang I. et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the SOFT trial. SABCS-2017. Abstr. GS4–03.

Fleming G., Francis P.A., Lang I. et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the SOFT trial. SABCS-2017. Abstr. GS4–03.

28.

28. Pagani O., Regan M.M., Fleming G.F. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials. SABCS-2017. Abstr. GS4–02.

Pagani O., Regan M.M., Fleming G.F. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials. SABCS-2017. Abstr. GS4–02.

29.

29. Lambertini M., Viglietti G., de Azambuja E. Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patiens with hormone receptor-positive breast cancer? ESMO OPEN 2018;3: e000350. DOI: 10.1136/esmoopen-2018–000350.

Lambertini M., Viglietti G., de Azambuja E. Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patiens with hormone receptor-positive breast cancer? ESMO OPEN 2018;3: e000350. DOI: 10.1136/esmoopen-2018–000350.

30.

30. Lambertini M. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine 2016;14:1. PMID: 26728489. DOI: 10.1186/s12916-015-0545-7.

Lambertini M. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine 2016;14:1. PMID: 26728489. DOI: 10.1186/s12916-015-0545-7.

31.

31. Lambertini M. Pooled analysis of five randomized trial investigating temporary ovarian suppression with gonadotropinreleasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. SABCS-2017. Abstr. GS4–01.

Lambertini M. Pooled analysis of five randomized trial investigating temporary ovarian suppression with gonadotropinreleasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. SABCS-2017. Abstr. GS4–01.

32.

32. Van Hellemond I.E.G., Vriens I.J.H., Peer P.G.M. et al. Ovarian function recovery during anastrozole in breast cancer patients with chemotherapyinduced ovarian function failure. J Natl Cancer Inst 2017;109(12). PMID: 29546343. DOI: 10.1093/jnci/djx074.

Van Hellemond I.E.G., Vriens I.J.H., Peer P.G.M. et al. Ovarian function recovery during anastrozole in breast cancer patients with chemotherapyinduced ovarian function failure. J Natl Cancer Inst 2017;109(12). PMID: 29546343. DOI: 10.1093/jnci/djx074.